What does “gene therapy for cholesterol” mean?
Everyday language covers many technologies. Here the topic is in vivo base editing aimed at reducing production of PCSK9, a protein that increases LDL-receptor degradation in the liver. The investigational goal is a single intravenous infusion that durably lowers PCSK9 and LDL-C. This research class differs from approved PCSK9 monoclonal antibodies or RNA-based therapies such as inclisiran.
Within current hyperlipidaemia / cholesterol treatment, lifestyle, statins, ezetimibe and, when appropriate, approved PCSK9-targeted medicines remain the backbone of practice. Base editing does not yet replace that backbone.
Why target PCSK9?
People with loss-of-function PCSK9 variants have lifelong lower LDL-C and fewer atherosclerotic events, which strengthened PCSK9 as a drug target. Monoclonal antibodies and inclisiran use this pathway pharmacologically. Base editing aims for more lasting gene-level inactivation; design intent is not the same as clinical proof.
How does VERVE-102 / base editing work?
VERVE-102 packages an mRNA encoding an adenine base-editor protein and a guide RNA targeting PCSK9 in a lipid nanoparticle that incorporates N-acetylgalactosamine, aiming liver delivery after one intravenous infusion. Unlike classic CRISPR double-strand cleavage, base editing seeks a targeted base change that disrupts gene function. Technical detail is not a prescription; the key point is that the platform remains investigational.
What question did Heart-2 ask?
Heart-2 (ClinicalTrials.gov: NCT06164730) is an open-label, phase 1b, single-ascending-dose study of VERVE-102 in adults with heterozygous familial hypercholesterolaemia (HeFH) or premature coronary artery disease who need further LDL lowering. The primary focus is safety; PCSK9 and LDL-C changes are pharmacodynamic measures.
Heart-2 key numbers
In the New England Journal of Medicine phase 1 analysis, 35 participants across six dose cohorts (0.3–1.0 mg total RNA/kg) had at least 28 days of follow-up. No dose-limiting toxic effects were reported. Mild-to-moderate infusion-related reactions and transient ALT elevations occurred; aspiration pneumonitis was reported in a participant with gastro-oesophageal reflux disease.
| Dose (mg/kg) | Mean PCSK9 reduction | Mean LDL-C reduction |
|---|---|---|
| 0.3 | 51% | 9% |
| 0.45 | — | 44% |
| 0.6 | — | 45% |
| 0.7 | — | 33% |
| 0.8 | — | 51% |
| 1.0 | 88% | 62% (absolute ≈78 mg/dL) |
PCSK9 reductions ranged from 51% at the lowest dose to 88% at the highest; intermediate PCSK9 percentages are summarised in the publication as part of the dose-dependent range. LDL-C reductions were dose-dependent. Effects appeared durable through follow-up; at least 1 year in 15 participants, with continuity up to 18 months noted in some institutional summaries. Small open-label phase 1b data do not prove reduction in clinical events.
Note: Earlier 2025 interim reports included fewer participants and a narrower dose range; the 35-participant NEJM analysis should be used as the current combined reading.
HEART-3 registry / trial status
HEART-3 (NCT07839936) is the phase 2 randomised, double-blind, placebo-controlled study of VERVE-102 (LY4636581). It will measure LDL-C change versus placebo in adults with atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk who need further LDL-C lowering.
- ClinicalTrials.gov status (last update 24 September 2026): NOT YET RECRUITING
- Estimated start: October 2026
- Estimated primary completion: August 2028
- Estimated enrolment: 175
- Age range: 18–70
- Primary endpoint: percent change from baseline in LDL-C
No results are posted yet; registry status can change. CT.gov should be rechecked when this article is updated.
How does this differ from approved therapies?
Statins, ezetimibe, PCSK9 monoclonal antibodies and inclisiran are guideline-supported tools. VERVE-102 is researched as a gene-editing class with a one-dose design. Lowering LDL in the laboratory is not the same evidence level as reducing heart attack or stroke. Markers such as lipoprotein(a) are a separate discussion; VERVE-102’s primary target is PCSK9 / LDL-C.
Safety and limitations
Absence of dose-limiting toxicity in Heart-2 does not mean “risk-free.” Infusion reactions, liver-enzyme changes and uncommon serious events are monitored. Long-term off-target effects, immune responses and follow-up plans extending up to 15 years are part of research protocols. Small samples, open-label design and selected populations limit generalisation.
What changes in practice today?
What changes today is information, not the treatment algorithm. In HeFH or high-risk dyslipidaemia, optimising proven therapies, adherence and secondary causes remains first. Experimental base editing belongs in clinical-trial and regulatory context — not a “one injection ends cholesterol” promise.
In brief: what do we know now?
VERVE-102 has early human data showing dose-dependent, sustained LDL-C lowering via PCSK9 base editing (Heart-2 / NEJM). HEART-3 phase 2 comparison has not yet started recruiting. The research is promising; the era of routine gene therapy for cholesterol has not begun.
Frequently asked questions
No. PCSK9 base-editing approaches such as VERVE-102 remain investigational. There is no approved routine “one-time gene therapy” for cholesterol. Current LDL-lowering options include statins, ezetimibe, PCSK9 monoclonal antibodies and inclisiran.
VERVE-102 is an investigational single-dose intravenous therapy that uses adenine base editing, delivered in a lipid nanoparticle, to target PCSK9 in the liver. The aim is lasting reduction of PCSK9 production and LDL-C. It is not an approved medicine.
Heart-2 (NCT06164730) evaluated 35 participants with HeFH or premature coronary disease across six dose cohorts. At the highest dose (1.0 mg/kg), mean PCSK9 fell by 88% and LDL-C by 62% (about 78 mg/dL absolute). Effects were dose-dependent; no dose-limiting toxic effects were reported. This does not equal approval or lifelong benefit for everyone.
HEART-3 (NCT07839936) is the phase 2 randomised, double-blind, placebo-controlled study of VERVE-102 (LY4636581). On ClinicalTrials.gov the status is NOT YET RECRUITING; estimated start October 2026, estimated primary completion August 2028, estimated enrolment 175.
No. Base editing aims to change a target DNA base without the classic double-strand break of CRISPR-Cas9 cleavage. VERVE-102 uses an adenine base editor.
Not at present. Base-editing research does not replace approved therapies. Approved medicines and lifestyle remain the foundation of clinical care.
The design aims for lasting PCSK9 inactivation. In Heart-2, reductions appeared sustained through follow-up (at least 1 year in some participants; up to 18 months in some reports). Larger phase 2/3 data are still needed for long-term and event outcomes.
Heart-2 studied selected adults with HeFH or premature CAD needing further LDL lowering. HEART-3 targets adults aged 18–70 with ASCVD or high ASCVD risk needing further LDL lowering. Participation depends on site and protocol criteria; this article is not a recruitment invitation.
Literature
References
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia. N Engl J Med. DOI: 10.1056/NEJMoa2601283 ClinicalTrials.gov: NCT06164730 (Heart-2). Primary source for Heart-2 PCSK9/LDL-C efficacy data.
Ambardekar AV, et al. Gene Editing Therapy in Cardiovascular Disease: A Scientific Statement From the American College of Cardiology. J Am Coll Cardiol. 2026. DOI: 10.1016/j.jacc.2026.02.5092
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. N Engl J Med. 2006;354:1264–1272. DOI: 10.1056/NEJMoa054013
HEART-3 — A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease. ClinicalTrials.gov: NCT07839936. Status accessed 1 Oct 2026: NOT_YET_RECRUITING.
Heart-2 Phase 1b protocol listing. ClinicalTrials.gov: NCT06164730. Status accessed 1 Oct 2026: RECRUITING.
2025 ESC/EAS Focused Update of the 2019 Guidelines for the management of dyslipidaemias. Eur Heart J. 2025. DOI: 10.1093/eurheartj/ehaf190 (context for current LDL-lowering care).
Eli Lilly and Company. Press release, 25 May 2026: VERVE-102 / Heart-2 programme and trial-status summary (not the primary source for efficacy figures; see the NEJM analysis).
Continue
